SVCM
CRNX icon

Saturn V Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Saturn V Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59,017
Closed -$1.98M – 25
2025
Q1 		$1.98M Sell
59,017
-108
-0.2% -$4.03K 1% 20
2024
Q4 		$3.02M Sell
59,125
-50,442
-46% -$2.82M 1.18% 20
2024
Q3 		$5.6M Sell
109,567
-370,114
-77% -$19.1M 2% 19
2024
Q2 		$21.5M Sell
479,681
-180,462
-27% -$8.33M 8.12% 3
2024
Q1 		$30.9M Sell
660,143
-126,989
-16% -$4.97M 12.39% 1
2023
Q4 		$28M Sell
787,132
-339,447
-30% -$10.4M 10.72% 2
2023
Q3 		$33.5M Buy
1,126,579
+187,902
+20% +$3.87M 14.02% 1
2023
Q2 		$16.9M Buy
938,677
+197,634
+27% +$3.94M 9.38% 2
2023
Q1 		$11.9M Buy
741,043
+117,224
+19% +$2.17M 8.89% 2
2022
Q4 		$11.3M Buy
+623,819
New +$11M 9.41% 1

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Saturn V Capital Management's CRNX Position: Q2 2025 in Review

Saturn V Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 59,017 shares — an estimated $1.98M sold.

Saturn V Capital Management first reported a position in CRNX in Q4 2022 and held it in 10 quarters. The position peaked at $33.5M in Q3 2023. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • Saturn V Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Saturn V Capital Management sold 59,017 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $1.98M.
  • Saturn V Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • Saturn V Capital Management's Crinetics Pharmaceuticals position peaked at $33.5M in Q3 2023.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Saturn V Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.